Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27845088 | 0.81 | RAB9A (0.41) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL18979820 | 0.79 | MAPT (0.37) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL30370409 | 0.79 | MAPT (0.37) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL799663 | 0.79 | ALDH1A1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL2638818 | 0.78 | NPC1 (0.47) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL31121580 | 0.76 | CTSB (0.56) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL1923229 | 0.76 | BACE1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL187124 | 0.76 | CTSB (0.56) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL28051995 | 0.76 | S1PR4 (0.52) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL13457247 | 0.76 | ALDH1A1 (0.38) | NPC1RAB9AMAPTSMN1; SMN2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309267-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2016-04-12 | — | — | US | disclosed |
| US-20140296534-A1 | COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS | ASTRAZENECA AB (SE) | 2014-10-02 | — | — | US | disclosed |
| US-8653274-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-20120264943-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-8193363-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | APP, PSEN1, PSEN2 | NPC1 65/4885RAB9A 2483/4885MAPT 5/4885 |
| US-20140296534-A1 | COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS | APP, PSEN1, PSEN2 | NPC1 65/4885RAB9A 2483/4885MAPT 5/4885 |
| US-20120264943-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | APP, PSEN1, PSEN2 | NPC1 65/4885RAB9A 2483/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.